NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
11/18/2025
Back to search
Official data from USPTO
GENSAVIS PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
02/14/2026
Trademark type
Combined
Nice classes
5
Filing date
06/24/2022
Registration date
08/08/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/08/2023
Last transaction
02/14/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
06/13/2022
First use in commerce
06/13/2022
Drawing code
3
Owner type
03
Owner location
Greenville, US
Examiner
SCHMIDT, JOHN JOSEPH
Current location
Historical data usage
Mark description
The mark consists of three interlocking rings to the left of the word Gensavis Pharmaceuticals stacked on top of each other.
Holders and representatives
Holders
Gensavis Pharmaceuticals, Inc.
Monsivais, LLC
Representatives
David M. Sigmon Michael Best & Friedrich LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicated and pharmaceutical preparationsdietary supplements containing iron for humans
Publications
History of USPTO decisions and trademark events.
26 publications found
C.7C
NEW CERTIFICATE UNDER SECTION 7 - PROCESSED
10/27/2025
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
10/23/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/13/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/13/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/13/2025
PRAM
POST REGISTRATION ACTION MAILED - SEC. 7
08/13/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/12/2025
ES7R
TEAS SECTION 7 REQUEST RECEIVED
04/02/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/08/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
08/08/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/23/2023
PUBO
PUBLISHED FOR OPPOSITION
05/23/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/03/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/19/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
04/19/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/19/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
04/19/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/19/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/14/2023
GNRT
NON-FINAL ACTION E-MAILED
04/14/2023
CNRT
NON-FINAL ACTION WRITTEN
04/14/2023
DOCK
ASSIGNED TO EXAMINER
04/07/2023
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
07/14/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/13/2022
NWAP
NEW APPLICATION ENTERED
06/28/2022
Continuous trademark protection
Get notified about every new filing that threatens GENSAVIS PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.